US FDA's Stein: 'Cognitive Dissonance' Exists Between Review Divisions In Regulation Of Biosimilars

 
• By Michael Cipriano
  
US FDA divisons have not yet achieved a consistent approach for regulating biosimilars, OND Director Peter Stein Says

More from Biosimilars

More from Biosimilars & Generics